These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31054211)

  • 1. Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis.
    Bhanvadia RR; Rodriguez J; Bagrodia A; Eggener SE
    BJU Int; 2019 Nov; 124(5):792-800. PubMed ID: 31054211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer.
    Patel HV; Srivastava A; Kim S; Patel HD; Pierorazio PM; Bagrodia A; Masterson TA; Ghodoussipour SB; Kim IY; Singer EA; Jang TL
    J Urol; 2022 May; 207(5):1057-1066. PubMed ID: 34978466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
    Woldu SL; Moore JA; Ci B; Freifeld Y; Clinton TN; Aydin AM; Singla N; Laura-Maria K; Hutchinson RC; Amatruda JF; Sagalowsky A; Lotan Y; Arriaga Y; Margulis V; Xie Y; Bagrodia A
    Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.
    Cary C; Pedrosa JA; Jacob J; Beck SD; Rice KR; Einhorn LH; Foster RS
    Cancer; 2015 Dec; 121(24):4369-75. PubMed ID: 26371446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014.
    Tabakin AL; Shinder BM; Kim S; Rivera-Nunez Z; Polotti CF; Modi PK; Sterling JA; Farber NJ; Radadia KD; Parikh RR; Kim IY; Saraiya B; Mayer TM; Singer EA; Jang TL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e194-e201. PubMed ID: 31818649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes.
    Patel HD; Joice GA; Schwen ZR; Semerjian A; Alam R; Srivastava A; Allaf ME; Pierorazio PM
    World J Urol; 2018 Jan; 36(1):73-78. PubMed ID: 29026972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
    Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A
    Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy.
    Mazzone E; Mistretta FA; Knipper S; Tian Z; Palumbo C; Gandaglia G; Soulieres D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1153-e1162. PubMed ID: 31515197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
    Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
    Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
    Heidenreich A; Paffenholz P; Nestler T; Pfister D
    Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.
    Taza F; Chovanec M; Snavely A; Hanna NH; Cary C; Masterson TA; Foster RS; Einhorn LH; Albany C; Adra N
    J Clin Oncol; 2020 Apr; 38(12):1338-1345. PubMed ID: 32134699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.
    Carver BS; Cronin AM; Eggener S; Savage CJ; Motzer RJ; Bajorin D; Bosl GJ; Sheinfeld J
    Urology; 2010 Jun; 75(6):1431-5. PubMed ID: 20299079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998-2011).
    Hugen CM; Hu B; Jeldres C; Burton C; Nichols CR; Porter CR; Daneshmand S
    Urol Oncol; 2016 Nov; 34(11):487.e7-487.e11. PubMed ID: 27372281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marital status independently predicts testis cancer survival--an analysis of the SEER database.
    Abern MR; Dude AM; Coogan CL
    Urol Oncol; 2012; 30(4):487-93. PubMed ID: 20870430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
    Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
    Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity.
    Syan-Bhanvadia S; Bazargani ST; Clifford TG; Cai J; Miranda G; Daneshmand S
    Eur Urol; 2017 Nov; 72(5):814-820. PubMed ID: 28325537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.